



## HYPHENS PHARMA INTERNATIONAL LIMITED

(Company Registration No. 201935688C)  
(Incorporated in the Republic of Singapore)

---

### GRANT OF SHARE AWARDS PURSUANT TO THE HYPHENS SHARE PLAN

---

The Board of Directors of Hyphens Pharma International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce that the Company had, on 8 December 2023, granted share awards (“**Awards**”) to eligible employees of the Group pursuant to Hyphens Performance Share Plan (“**HSP**”).

In accordance with Rule 704(32) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited, the details of the grant of Awards are as follows:

(a)	Date of grant of Awards:	8 December 2023
(b)	Number of Shares which are the subject of the Awards:	Contingent awards in respect of 5,854,418 shares (“ <b>New Shares</b> ”)
(c)	Consideration payable for grant of Awards	None
(d)	Market price (last done price per share) of shares on the date of grant of Awards:	S\$0.28
(e)	Number of Shares which are the subject of the Awards granted to each Director and/or controlling shareholder (and their associates), if any:	Mr. Lim See Wah, Executive Chairman and Chief Executive Officer as well as a controlling shareholder of the Company, has been granted a contingent award in respect of 2,137,118 shares, subject to shareholders’ approval to be obtained in due course.
(f)	Vesting period:	The actual number of HSP final awards of fully paid ordinary shares will range from 0% to 120% of the New Shares and is subject to achievements against targets over a three-year performance period (up to the financial year ending 31 December 2025) and other terms and conditions being met.

The New Shares awarded shall have a sale restriction moratorium period of one year from the date of issue.

BY ORDER OF THE BOARD

Flora Zhang  
Chief Financial Officer

8 December 2023

---

*This announcement has been reviewed by the Company’s Sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.*